Research finds ZFP148 regulates CD8+ T cell differentiation, enhancing tumor response in cancer immunotherapy.
Progenitor CD8 + T cells differentiate into effector and exhausted progenies during chronic antigen stimulation; however, mechanisms that restrain exhaustion and sustain effector differentiation remain incompletely defined. Here we identified the transcription factor ZFP148 as a repressor of CD8 + T cell effector differentiation. ZFP148-deficient CD8 + T cells displayed increased frequency of cytolytic effector cells and reduced frequency of exhausted cells compared with Zfp148 fl/fl controls during chronic viral infection. Mechanistically, ZFP148 limited the chromatin accessibility of effector-driving transcription factor motifs and directly repressed expression of the transcription factor KLF2. Furthermore, conditional ZFP148 ablation in CD8 + T cells synergized with programmed cell death-1 blockade to improve tumor control in syngeneic mouse models. Consistently, cancer patients with lower ZNF148 expression in tumor-infiltrating CD8 + T cells showed improved responsiveness to immunotherapies. Collectively, our study identifies ZFP148 as a transcriptional repressor of CD8 + T cell effector differentiation and highlights its therapeutic potential for enhancing antitumor immunity.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: